GLP1R and type 2 diabetes mellitus: The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of pharmaceuticals are highly effective agents for the treatment of T2D and for achieving weight loss.4,5,6,7,8,9 GLP-1RAs have further been shown to reduce the risk of adverse cardiovascular outcomes in patients with obesity10 and to contribute to the resolution of nonalcoholic steatohepatitis.11 Because of their efficacy in controlling T2D, obesity, and related comorbidities, we hypothesized that these agents might reduce the risk of the OACs.